Proteomics International is rolling out a commercial roadmap with a four-test diagnostics suite targeting kidney disease, ...
Lumos Diagnostics has received a strong endorsement from Foster Stockbroking, which increased its price target from 42 cents to 51 cents after the company achieved a key regulatory milestone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results